Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903733 · ClinicalTrials.gov registry record · NA
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
A NA study, sponsored by Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 281
- Enrollment target
NCT01903733: Completed NA study, sponsored by Pfizer.
NCT01903733 is a NA study that has completed, run by Pfizer. The registered enrollment target is 281 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01903733, a NA study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 281 participants
- Enrollment target
Study Summary
The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.
Primary Outcome
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital a
Interventions
- DRUG bosutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2013-08-28 |
| Est. Completion | 2020-06-05 |
| Phase | NA |
What the finished NCT01903733 record still lists
NCT01903733 is an interventional study that assigns participants to a tested intervention. The registered 281 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which bosutinib is the first listed.
NCT01903733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01903733 about?
NCT01903733 is a clinical study titled "Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008". The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.
What is the current status of trial NCT01903733?
This trial is currently completed. It is a NA study. The enrollment target is 281 participants. The study started on 2013-08-28. Estimated completion is 2020-06-05.
What interventions are being tested in trial NCT01903733?
The interventions under investigation include: bosutinib (DRUG).
Who is sponsoring clinical trial NCT01903733?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01903733's enrollment target sits among peer trials
281 380th of 2000 higher than 1,621 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04521231 · 281 participants · Phase 1
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- NCT06190730 · 281 participants · NA
REmote Symptom COllection to improVE postopeRative Care
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI